-
EP4193153
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4193153
| EP4193153 - INFLAMMATORY CYTOKINES AND FATIGUE IN SUBJECT WITH A COMPLEMENT MEDIATED DISEASE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 12.05.2023 Database last updated on 02.11.2024 | |
| Former | The international publication has been made Status updated on 11.02.2022 | ||
| Former | unknown Status updated on 24.09.2021 | Most recent event Tooltip | 12.06.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Bioverativ USA Inc. 225 Second Avenue Waltham, MA 02451 / US | [2023/24] | Inventor(s) | 01 /
ARIAS, Jaime, Morales Waltham, MA 02451 / US | 02 /
HOBBS, William, E. Waltham, MA 02451 / US | 03 /
STOREK, Michael, J. Waltham, MA 02451 / US | 04 /
PATEL, Parija, S. Waltham, MA 02451 / US | [2023/24] | Representative(s) | Zwicker, Jörk ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [2023/24] | Application number, filing date | 21770091.3 | 05.08.2021 | [2023/24] | WO2021US44761 | Priority number, date | US202063062243P | 06.08.2020 Original published format: US 202063062243 P | [2023/24] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022031978 | Date: | 10.02.2022 | Language: | EN | [2022/06] | Type: | A1 Application with search report | No.: | EP4193153 | Date: | 14.06.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.02.2022 takes the place of the publication of the European patent application. | [2023/24] | Search report(s) | International search report - published on: | EP | 10.02.2022 | Classification | IPC: | G01N33/68 | [2023/24] | CPC: |
G01N33/6869 (EP,IL,KR);
C07K16/40 (US);
A61P7/00 (EP,IL,KR,US);
C07K16/18 (EP,IL,KR);
G01N33/6893 (EP,IL,KR,US);
A61K2039/505 (KR);
C07K2317/52 (US);
G01N2333/5412 (EP,IL,KR,US);
G01N2333/5428 (EP,IL,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/24] | Extension states | BA | 26.01.2023 | ME | 26.01.2023 | Validation states | MA | 26.01.2023 | Title | German: | ENTZÜNDUNGSZYTOKINE UND ERMÜDUNG BEI PATIENTEN MIT KOMPLEMENTVERMITTELTER ERKRANKUNG | [2023/24] | English: | INFLAMMATORY CYTOKINES AND FATIGUE IN SUBJECT WITH A COMPLEMENT MEDIATED DISEASE | [2023/24] | French: | CYTOKINES INFLAMMATOIRES ET FATIGUE CHEZ UN SUJET ATTEINT D'UNE MALADIE MÉDIÉE PAR COMPLÉMENT | [2023/24] | Entry into regional phase | 26.01.2023 | National basic fee paid | 26.01.2023 | Designation fee(s) paid | 26.01.2023 | Examination fee paid | Examination procedure | 26.01.2023 | Examination requested [2023/24] | 26.01.2023 | Date on which the examining division has become responsible | 25.09.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 14.06.2023 | Renewal fee patent year 03 | 12.06.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2016326237 (ROSENTHAL ARNON [US], et al) [A] 1-23 * claim 1b *; | [A]WO2019198807 (CHUGAI PHARMACEUTICAL CO LTD [JP]) [A] 1-23 * paragraph [0032] *; | [A]US2020048332 (PANICKER SANDIP [US], et al) [A] 20-22 * the whole document, in particular claims *; | [I] - RÖTH A ET AL, "Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study", BLOOD, (20191121), vol. 134, doi:10.1182/BLOOD-2019-132490, XP086604281 [I] 1-23 * the whole document, in particular page 2, last 6 lines; "Conclusions" spanning pages 3 and 4;; figures 1A, 1B * DOI: http://dx.doi.org/10.1182/blood-2019-132490 | [A] - YIOU TSENG ET AL, "PROBING THE STRUCTURE OF Cl WITH AN ANTI-Cls MONOCLONAL ANTIBODY: THE POSSIBLE EXISTENCE OF TWO FORMS OF Cl IN SOLUTION", MOLECULAR IMMUNOLOGY, (19970101), vol. 34, no. 8/9, pages 671 - 679, XP055246713 [A] 1-23 * abstract * | [XPI] - WEITZ I C ET AL, "Inflammation and Fatigue in Patients with Cold Agglutinin Disease (CAD): Analysis from the Phase 3 Cardinal Study", BLOOD, vol. 136, no. Supplement 1, doi:10.1182/blood-2020-140335, (20201105), pages 7 - 8, URL: https://ashpublications.org/blood/article/136/Supplement%201/7/470549/Inflammation-and-Fatigue-in-Patients-with-Cold, XP055859968 [XP] 1-19,23 * the whole document * [I] 20-22 DOI: http://dx.doi.org/10.1182/blood-2020-140335 | by applicant | WO8601533 | US4816567 | US4816397 | US4946778 | EP0125023 | EP0519596 | WO9306213 | US5225539 | EP0120694 | EP0194276 | EP0239400 | WO9429351 | US5476786 | US5514548 | US5585097 | US5624821 | US5648260 | WO9734631 | US5677425 | WO9823289 | US5869046 | WO0042072 | US6121022 | US6165745 | US6194551 | US6277375 | WO02060919 | US6737056 | US7658921 | US8591886 | WO2014071206 | WO2016164358 | WO2018170145 | - BERENTSEN S, Semin Hematol., (20180000), vol. 55, no. 3, pages 141 - 149 | - NORIS MREMUZZI G, Semin Nephrol., (20130000), vol. 33, no. 6, pages 479 - 492 | - CELLA et al., Cancer, (20020000), vol. 94, no. 2, pages 528 - 238 | - YELLEN et al., J Pain Symptom Manage, (19970000), vol. 13, no. 2, pages 63 - 74 | - LAI et al., JRheumatol, (20110000), vol. 38, no. 4, pages 672 - 9 | - REDDY et al., JPalliatMed, (20070000), vol. 19, no. 5, pages 1068 - 75 | - WHITEHEAD, J Pain Symptom Manage, (20090000), vol. 37, no. 1, pages 10 - 7,28 | - HJOLLUND et al., Health Qual Life Outcomes, (20070000), vol. 5, page 12 | - ZAPATA et al., Protein Eng., (19950000), vol. 8, no. 10, pages 1057 - 1062 | - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, Springer-Verlag,, (19940000), vol. 113, pages 269 - 315 | - HOLLINGER et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448 | - LEFRANC et al., Developmental and Comparative Immunology, (20030000), vol. 27, page 55 | - KABAT et al., J. Biol. Chem., (19770000), vol. 252, pages 6609 - 6616 | - CHOTHIA et al., J. Mol. Biol., (19870000), vol. 196, pages 901 - 917 | - MACCALLUM et al., J. Mol. Biol., (19960000), vol. 262, pages 732 - 745 | - BIRD, R. E. et al., Science, (19880000), vol. 242, pages 423 - 426 | - KAMMAN, M. et al., Nucl. Acids Res., (19890000), vol. 17, page 5404 | - SATO, K. et al., Cancer Research, (19930000), vol. 53, pages 851 - 856 | - DAUGHERTY, B. L. et al., Nucleic Acids Res., (19910000), vol. 19, no. 9, pages 2471 - 2476 | - LEWIS, A. P.J. S. CROWE, Gene, (19910000), vol. 101, pages 297 - 302 | - SMITH P et al., PNAS, (20120000), vol. 109, pages 6181 - 6186 | - DALL'ACQUA W F et al., J Biol Chem, (20060000), vol. 281, pages 23514 - 24 | - ZALEVSKY et al., Nat Biotechnol., (20100200), vol. 28, no. 2, pages 157 - 159 | - SHIELDS R L et al., J Biol Chem, (20010000), vol. 276, pages 6591 - 604 | - ANGAL S. et al., "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody", Mol Immunol, (19930000), vol. 30, doi:10.1016/0161-5890(93)90432-B, pages 105 - 108, XP023683005 DOI: http://dx.doi.org/10.1016/0161-5890(93)90432-B | - BENHNIA et al., JOURNAL OF VIROLOGY, (20091200), pages 12355 - 12367 | - CHEN, Drug Dev Ind Pharm, (19920000), vol. 18, pages 1311 - 54 | - ROTH A et al., N Engl J Med., (20210000), vol. 384, no. 14, pages 1323 - 1334 | - SCHREZENMEIER H et al., Haematologica, (20140000), vol. 99, no. 5, pages 922 - 929 | - ESCALANTE CP et al., Cancer Med., (20190000), vol. 8, no. 2, pages 543 - 553 |